Search Antibody Database

Found 1 matching record:

Displaying record number 771

Download this epitope record as JSON.

MAb ID	clone 3 (CL3)
HXB2 Location	gp160(597-606) DNA(8013..8042)	gp160 Epitope Map
Author Location	gp41(597-606)
Research Contact	BioClonetics (Philadelphia)
Epitope	GCSGKLICTT	Epitope Alignment
Subtype	B
Ab Type
Neutralizing	L P
Species (Isotype)	human(IgG1)
Patient
Immunogen	HIV-1 infection
Keywords	antibody binding site, neutralization, rate of progression, responses in children, review, subtype comparisons, vaccine antigen design, variant cross-reactivity

Notes

Showing 8 of 8 notes.

• Clone 3: This review summarizes Clone 3 Ab epitope, properties and neutralization activity. Kramer2007 (review)
• Clone 3: This review summarizes data on the role of NAb in HIV-1 infection and the mechanisms of Ab protection, data on challenges and strategies to design better immunogens that may induce protective Ab responses, and data on structure and importance of MAb epitopes targeted for immune intervention. The importance of standardized assays and standardized virus panels in neutralization and vaccine studies is also discussed. Srivastava2005 (antibody binding site, neutralization, vaccine antigen design, review)
• Clone 3: This review focuses on the importance of neutralizing Abs in protecting against HIV-1 infection, including mechanisms of Ab interference with the viral lifecycle, Ab responses elicited during natural HIV infection, and use of monoclonal and polyclonal Abs in passive immunization. In addition, vaccine design strategies for eliciting of protective broadly neutralizing Abs are discussed. MAbs included in this review are: 2F5, Clone 3 (CL3), 4E10, Z13, IgG1b12, 2G12, m14, 447-52D, 17b, X5, m16, 47e, 412d, E51, CM51, F105, F425, 19b, 2182, DO142-10, 697-D, 448D, 15e and Cβ1. McCann2005 (antibody binding site, neutralization, variant cross-reactivity, review)
• clone 3: Called CL3 here. Nabs against HIV-1 M group isolates were tested for their ability to neutralize 6 randomly selected HIV-1 O group strains. Clone 3 could neutralize some O group strains. CL3 is specific for a linear epitope containing 2 cysteines that generate a loop that could be important during the fusion of the virus with the target cell. This epitope is represented as GCxGxxxCxT HIV-1 group O isolates. Ferrantelli2004a (variant cross-reactivity)
• clone 3: One of 24 MAbs and Fabs in this database that bind to the highly immunogenic gp41 cluster I region (aa 579 - 604). Only one of these has any neutralizing potential, clone 3. clone 3 neutralized 3 diverse B clade TCLA strains and 3 primary O group strains. Gorny2003 (variant cross-reactivity, review, subtype comparisons)
• clone 3: Monoclonal antibodies to this epitope have distinct phenotypes---41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing, and clone 3 beneficial. Database note: First author "EnshellSeijffers" is also found as "Enshell-Seijffers" on annotated papers in this database. EnshellSeijffers2001 (variant cross-reactivity)
• clone 3: Inhibits replication of three diverse HIV-1 laboratory strains, as well as an AZT-resistant isolate. Cotropia1996 (variant cross-reactivity)
• clone 3: Core binding domain gcsgkLIC -- lack of serological activity to this region correlates with rapid progression in infants (Broliden1989) Cotropia1992. Broliden1989,Cotropia1992 (antibody binding site, responses in children, rate of progression)

References

Showing 9 of 9 references.

Broliden1989 P. A. Broliden, V. Moschese, K. Ljunggren, J. Rosen, C. Fundaro, A. Plebani, M. Jondal, and P. Rossi. Diagnostic Implication of Specific Immunoglobulin G Patterns of Children Born to HIV-1 Infected Mothers. AIDS, 3:577, 1989. PubMed ID: 2551341. Show all entries for this paper.

Cotropia1992 J. Cotropia, K. E. Ugen, D. Lambert, K. Ljunggren-Broliden, S. Kliks, J. Hoxie, and D. B. Weiner. Characterization of Human Monoclonal Antibodies to the HIV-1 Transmembrane gp41 Protein. Vaccines 92, :157-163, 1992. Editors: F. Brown, H. S. Ginsberg and R. Lerner, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Show all entries for this paper.

Cotropia1996 J. Cotropia, K. E. Ugen, S. Kliks, K. Broliden, P.-A. Broliden, J. A. Hoxie, V. Srikantan, W. V. Williams, and D. B. Weiner. A Human Monoclonal Antibody to HIV-1 gp41 with Neutralizing Activity Against Diverse Laboratory Isolates. J. Acquir. Immune Defic. Syndr., 12:221-232, 1996. PubMed ID: 8673526. Show all entries for this paper.

EnshellSeijffers2001 David Enshell-Seijffers, Larisa Smelyanski, Nurith Vardinon, Israel Yust, and Jonathan M. Gershoni. Dissection of the Humoral Immune Response Toward an Immunodominant Epitope of HIV: A Model for the Analysis of Antibody Diversity in HIV+ Individuals. FASEB J., 15(12):2112-1220, Oct 2001. PubMed ID: 11641237. Show all entries for this paper.

Ferrantelli2004a Flavia Ferrantelli, Moiz Kitabwalla, Robert A. Rasmussen, Chuanhai Cao, Ting-Chao Chou, Hermann Katinger, Gabriela Stiegler, Lisa A. Cavacini, Yun Bai, Joseph Cotropia, Kenneth E. Ugen, and Ruth M. Ruprecht. Potent Cross-Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodies--Implications for Acquired Immunodeficiency Syndrome Vaccine. J. Infect. Dis., 189(1):71-74, 1 Jan 2004. PubMed ID: 14702155. Show all entries for this paper.

Gorny2003 Miroslaw K. Gorny and Susan Zolla-Pazner. Human Monoclonal Antibodies that Neutralize HIV-1. In Bette T. M. Korber and et. al., editors, HIV Immunology and HIV/SIV Vaccine Databases 2003. pages 37--51. Los Alamos National Laboratory, Theoretical Biology \& Biophysics, Los Alamos, N.M., 2004. URL: http://www.hiv.lanl.gov/content/immunology/pdf/2003/zolla-pazner_article.pdf. LA-UR 04-8162. Show all entries for this paper.

Kramer2007 Victor G. Kramer, Nagadenahalli B. Siddappa, and Ruth M. Ruprecht. Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes. Curr. HIV Res., 5(6):642-55, Nov 2007. PubMed ID: 18045119. Show all entries for this paper.

McCann2005 C. M. Mc Cann, R. J. Song, and R. M. Ruprecht. Antibodies: Can They Protect Against HIV Infection? Curr. Drug Targets Infect. Disord., 5(2):95-111, Jun 2005. PubMed ID: 15975016. Show all entries for this paper.

Srivastava2005 Indresh K. Srivastava, Jeffrey B. Ulmer, and Susan W. Barnett. Role of Neutralizing Antibodies in Protective Immunity Against HIV. Hum. Vaccin., 1(2):45-60, Mar-Apr 2005. PubMed ID: 17038830. Show all entries for this paper.